National Health (Chemotherapy Pharmaceuticals Access Program) Special Arrangement 2010 (No. PB 117 of 2010)
37Additional patient contributions
Start here
Get a plain-English read of 37
Turn the raw legal text into a practical explanation grounded in National Health (Chemotherapy Pharmaceuticals Access Program) Special Arrangement 2010 (No. PB 117 of 2010).
37 Additional patient contributions
(1) For paragraph 35 (2) (b), the amount is the amount calculated by subtracting the amount for the chemotherapy pharmaceutical benefit mentioned in the column in Schedule 4 headed ‘Approved Ex-manufacturer Price’ from the amount mentioned for the chemotherapy pharmaceutical benefit in the column in Schedule 4 headed ‘Claimed Ex-manufacturer Price’.
(2) However, if the quantity of the chemotherapy pharmaceutical benefit being supplied is for more or less than the quantity mentioned in the column in Schedule 4 headed ‘Quantity or Number of Units’, the amounts mentioned in the columns in Schedule 4 headed ‘Approved Ex-manufacturer Price’ and ‘Claimed Ex-manufacturer Price’ must be adjusted proportionally.